Terms: = Prostate cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Prognosis
55 results:
1. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
2. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
3. Targeting DNA methylation and B7-H3 in rb1-deficient and neuroendocrine prostate cancer.
Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
[TBL] [Abstract] [Full Text] [Related]
4. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S; Fang L; McGowen K; Yin J; Bowman J; Ku AT; Alilin AN; Corey E; Roudier MP; True LD; Dumpit R; Coleman I; Lee JK; Nelson PS; Capaldo BJ; Mariani A; Hoover C; Senatorov IS; Beshiri M; Sowalsky AG; Hurt EM; Kelly K
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37725435
[TBL] [Abstract] [Full Text] [Related]
6. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract] [Full Text] [Related]
7. Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic prostate cancer.
Fang S; Zhe S; Lin HM; Azad AA; Fettke H; Kwan EM; Horvath L; Mak B; Zheng T; Du P; Jia S; Kirby RM; Kohli M
JCO Clin Cancer Inform; 2023 Jul; 7():e2300057. PubMed ID: 37490642
[TBL] [Abstract] [Full Text] [Related]
8. The Genomic and Epigenomic Landscape of Double-Negative Metastatic prostate cancer.
Lundberg A; Zhang M; Aggarwal R; Li H; Zhang L; Foye A; Sjöström M; Chou J; Chang K; Moreno-Rodriguez T; Shrestha R; Baskin A; Zhu X; Weinstein AS; Younger N; Alumkal JJ; Beer TM; Chi KN; Evans CP; Gleave M; Lara PN; Reiter RE; Rettig MB; Witte ON; Wyatt AW; Feng FY; Small EJ; Quigley DA
Cancer Res; 2023 Aug; 83(16):2763-2774. PubMed ID: 37289025
[TBL] [Abstract] [Full Text] [Related]
9. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine prostate cancer Coexisting with Androgen Receptor Pathway prostate cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract] [Full Text] [Related]
10. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W
Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492
[TBL] [Abstract] [Full Text] [Related]
11. BET Inhibition Sensitizes Immunologically Cold Rb-Deficient prostate cancer to Immune Checkpoint Blockade.
Olson BM; Chaudagar K; Bao R; Saha SS; Hong C; Li M; Rameshbabu S; Chen R; Thomas A; Patnaik A
Mol Cancer Ther; 2023 Jun; 22(6):751-764. PubMed ID: 37014264
[TBL] [Abstract] [Full Text] [Related]
12. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
13. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract] [Full Text] [Related]
14. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
[TBL] [Abstract] [Full Text] [Related]
16. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, rb1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract] [Full Text] [Related]
17. prognosis Associated With Luminal and Basal Subtypes of Metastatic prostate cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract] [Full Text] [Related]
18. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant prostate cancer.
Chai S; Matsumoto N; Storgard R; Peng CC; Aparicio A; Ormseth B; Rappard K; Cunningham K; Kolatkar A; Nevarez R; Tu KH; Hsu CJ; Malihi P; Corn P; Zurita A; Hicks J; Kuhn P; Ruiz-Velasco C
Mol Cancer Res; 2021 Dec; 19(12):2036-2045. PubMed ID: 34462330
[TBL] [Abstract] [Full Text] [Related]
19. Syndecan Family Gene and Protein Expression and Their Prognostic Values for prostate cancer.
Santos NJ; Barquilha CN; Barbosa IC; Macedo RT; Lima FO; Justulin LA; Barbosa GO; Carvalho HF; Felisbino SL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445387
[TBL] [Abstract] [Full Text] [Related]
20. Elucidating prostate cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Sumanasuriya S; Seed G; Parr H; Christova R; Pope L; Bertan C; Bianchini D; Rescigno P; Figueiredo I; Goodall J; Fowler G; Flohr P; Mehra N; Neeb A; Rekowski J; Eisenberger M; Sartor O; Oudard S; Geffriaud-Ricouard C; Ozatilgan A; Chadjaa M; Macé S; Lord C; Baxter J; Pettitt S; Lambros M; Sharp A; Mateo J; Carreira S; Yuan W; de Bono JS
Eur Urol; 2021 Aug; 80(2):243-253. PubMed ID: 34103179
[TBL] [Abstract] [Full Text] [Related]
[Next]
